Previous close | 0.4500 |
Open | N/A |
Bid | 0.0000 |
Ask | 0.5000 |
Strike | 12.50 |
Expiry date | 2024-12-20 |
Day's range | 0.4500 - 0.4500 |
Contract range | N/A |
Volume | |
Open interest | 1 |
PISCATAWAY, N.J., July 01, 2024--Kashiv BioSciences, LLC ("Kashiv" or the "Company") today announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR®, with Amneal Pharmaceuticals, Inc. ("Amneal") for the United States.
BRIDGEWATER, N.J., July 01, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the addition of omalizumab, referencing XOLAIR®, to its biosimilar pipeline.
BRIDGEWATER, N.J., June 28, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the release of its fourth (2023) Environmental, Social and Governance (ESG) Report. This 2023 report provides a look at our progress against our core ESG priorities, including our commitment to embedding sustainability across our business; human capital management, including well-being, inclusion and belonging efforts; philanthropic partnerships with health-related non-profit